In addition, although most patients respond to EGFR-TKI treatment, the duration of the response is inconsistent between individual cases, and it is expected that pre-existing genetic abnormalities in cancer cells may affect the outcome of EGFR-TKI treatment [1,2,3]. This evidence concerns the gene EGFR and cancer.